References
- https://www.formularywatch.com/view/fda-approves-sndas-for-vazalore
- https://www.empr.com/home/news/vazalore-snda-approved-liquid-filled-aspirin-capsule/
- de Abajo Fj, García Rodríguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2001;1:1. Epub 2001 Feb 13. PMID: 11228592; PMCID: PMC32172
- Bhatt DL, Grosser T, Dong JF, et al. Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2017 Feb 14;69(6):603–612. Epub 2017 Jan 11. PMID: 28089180.
- Cryer B, Bhatt DL, Lanza FL, et al. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol. 2011Feb;106(2):272–277. Epub 2010 Nov 16. PMID: 21081908
- Angiolillo DJ, Bhatt DL, Lanza F, et al. Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study. J Thromb Thrombolysis. 2019Nov;48(4):554–562. PMID: 31420787; PMCID: PMC6800884
- Grosser T, Fries S, Lawson JA, et al. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013 Jan 22;127(3):377–385. Epub 2012 Dec 4. PMID: 23212718; PMCID: PMC3552520.
- https://www.empr.com/?s=vazalore
- Capodanno D, Angiolillo DJ. Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus. Circulation. 2016;134:1579–1594.
- Bowman L, Mafham M, Wallendszus K, et al. ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529–1539. PubMed: 30146931
- Gaziano JM, Brotons C, Coppolecchia R, et al. ARRIVE executive committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomized, double-blind, placebo-controlled trial. Lancet. 2018;392:1036–1046. PubMed: 30158069.
- McNeil JJ, Woods RL, Nelson MR, et al. ASPREE Investigator Group. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med. 2018;379:1499–1508. [PubMed: 30221596]
- Arnett DK, Blumenthal RS, Albert MA, et al. ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;74(10):e177–e232.
- American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(January suppl 1):S103–S123. 10.
- American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(suppl 1):S125–S150. 10.
- US Preventive Services Task Force. Aspirin use to prevent cardiovascular disease us preventive services task force recommendation statement. JAMA. 2022;327(16): 1577–1584.
- O’Brien CW, Juraschek SP, Wee CC. Prevalence of aspirin use for primary prevention of cardiovascular disease in the United States: results from the 2017 National Health Interview Survey. Ann Intern Med. 2019 Oct 15;171(8):596–598. Epub 2019 Jul 23. PMID: 31330542; PMCID: PMC7251544
- https://ir.plxpharma.com/news-releases/news-release-details/plx-pharma-receives-fda-approval-sndas-both-vazalore-325-mg-and
- https://www.cdc.gov/heartdisease/facts.htm
- https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1